{
    "content": "Diagnosis:\n\nTreatment:\n\nMar 23 Right breast invasive ductal carcinoma, 28mm primary lesion with extensive intraductal component (35mm), presence of lymphovascular space invasion\n\nER 0%, PR 0%, HER2 3+ on immunohistochemistry\n\n20.03.23 Axillary node biopsy positive (3/15 nodes involved)\n\nInitial staging workup negative for distant metastatic disease\n\nMar 23 Right mastectomy with axillary clearance\n\nApr 23 Commenced on dose-dense AC-T protocol (4 cycles dose-dense adriamycin/cyclophosphamide followed by 4 cycles of weekly paclitaxel)\n\nMay 23 Developed grade 4 neutropenia after cycle 2 AC,\ncommenced on pegfilgrastim prophylaxis for subsequent cycles\n\nPaclitaxel initiated at standard dose but reduced to 75% from week 2 due to\ngrade 3 peripheral neuropathy and grade 2 hepatic dysfunction\n12.07.23 Completed systemic therapy\n\n15.08.23 Completed course of chest wall radiotherapy\n\nCurrent situation: | Jul 23 Screened for KATHERINE-2 protocol but ineligible due to baseline\n\ncardiac ejection fraction of 51% (protocol requirement >55%)\n\n20.07.23 Initiated adjuvant trastuzumab therapy\n\n10.08.23 Surveillance CT imaging showed post-surgical changes only\n25.08.23 Isotope bone scan demonstrated focal uptake in T11 vertebra\n\n10.09.23 Spine MRI showed degenerative disc disease at T11/12 with\nmoderate foraminal stenosis, no evidence of metastatic involvement. Widespread\nosteoporotic changes noted\n\n15.09.23 DEXA scanning confirmed severe osteoporosis (T-score -3.4 at lumbar spine)\n\nInitiating monthly zoledronic acid therapy\nMaintaining adjuvant trastuzumab treatment\nDue for cycle 5 of planned 17 cycles\n30.09.23 Scheduled for cardiac monitoring and surveillance imaging\n\nI saw [redacted name] in clinic today. She describes persistent grade 2 sensory neuropathy affecting her hands and chronic fatigue syndrome. Her cardiac function is stable with no clinical evidence of cardiac dysfunction.\n\n[redacted name] is managing well with cycle 5 of adjuvant trastuzumab and will undergo repeat cardiac assessment on 30 September 2023 alongside planned CT evaluation. We will coordinate concurrent mammographic assessment.\n\n[redacted name] will return to clinic after completion of these investigations to review results and discuss ongoing management strategy.",
    "output": {
        "primary_cancer": {
            "site": "breast, right",
            "year": 2023,
            "month": 3,
            "histopathology_status": "28mm invasive ductal carcinoma with extensive intraductal component (35mm), lymphovascular space invasion present",
            "biomarker_status": "ER 0%, PR 0%, HER2 3+ positive",
            "cancer_timeline": [
                {
                    "type": "treatment_surgery",
                    "value": "Right mastectomy with axillary clearance - 3/15 nodes positive",
                    "year": 2023,
                    "month": 3
                },
                {
                    "type": "treatment_systemic_start",
                    "value": "Commenced on dose-dense AC-T protocol (4 cycles dose-dense adriamycin/cyclophosphamide followed by 4 cycles of weekly paclitaxel)",
                    "year": 2023,
                    "month": 4
                },
                {
                    "type": "treatment_systemic_change",
                    "value": "Developed grade 4 neutropenia after cycle 2 AC, commenced on pegfilgrastim prophylaxis",
                    "year": 2023,
                    "month": 5
                },
                {
                    "type": "treatment_systemic_change",
                    "value": "Paclitaxel reduced to 75% due to grade 3 peripheral neuropathy and grade 2 hepatic dysfunction",
                    "year": 2023,
                    "month": 5
                },
                {
                    "type": "treatment_systemic_change",
                    "value": "Completed systemic therapy",
                    "year": 2023,
                    "month": 7
                },
                {
                    "type": "treatment_radiotherapy",
                    "value": "Completed course of chest wall radiotherapy",
                    "year": 2023,
                    "month": 8
                },
                {
                    "type": "clinical_trial_update",
                    "value": "Screened for KATHERINE-2 protocol but ineligible due to baseline cardiac ejection fraction of 51%",
                    "year": 2023,
                    "month": 7
                },
                {
                    "type": "treatment_systemic_start",
                    "value": "Initiated adjuvant trastuzumab therapy",
                    "year": 2023,
                    "month": 7
                },
                {
                    "type": "investigation_finding",
                    "value": "Surveillance CT imaging showed post-surgical changes only",
                    "year": 2023,
                    "month": 8
                },
                {
                    "type": "anatomical_finding",
                    "value": "Isotope bone scan demonstrated focal uptake in T11 vertebra",
                    "year": 2023,
                    "month": 8
                },
                {
                    "type": "investigation_finding",
                    "value": "Spine MRI showed degenerative disc disease at T11/12 with moderate foraminal stenosis, no evidence of metastatic involvement, widespread osteoporotic changes",
                    "year": 2023,
                    "month": 9
                },
                {
                    "type": "laboratory_finding",
                    "value": "DEXA scanning confirmed severe osteoporosis (T-score -3.4 at lumbar spine)",
                    "year": 2023,
                    "month": 9
                },
                {
                    "type": "treatment_systemic_start",
                    "value": "Initiating monthly zoledronic acid therapy",
                    "year": 2023,
                    "month": 9
                }
            ]
        },
        "patient_facts": [
            {
                "type": "current_symptom",
                "value": "grade 2 sensory neuropathy affecting hands"
            },
            {
                "type": "current_symptom",
                "value": "chronic fatigue syndrome"
            },
            {
                "type": "investigation_finding",
                "value": "cardiac function is stable with no clinical evidence of cardiac dysfunction"
            }
        ],
        "status_updates": [
            {
                "type": "clinical_summary",
                "value": "HER2-positive breast cancer treated with mastectomy, adjuvant chemotherapy and radiotherapy, now on maintenance trastuzumab. Patient tolerating cycle 5/17 of adjuvant trastuzumab with stable cardiac function, though experiencing persistent chemotherapy-induced peripheral neuropathy."
            },            
            {
                "type": "latest_treatment_toxicity",
                "value": "grade 2 sensory neuropathy affecting hands"
            },
            {
                "type": "update_to_treatment",
                "value": "managing well with cycle 5 of adjuvant trastuzumab"
            },
            {
                "type": "planned_investigation",
                "value": "cardiac assessment, CT evaluation and mammographic assessment scheduled for 30.09.23"
            },
            {
                "type": "follow_up_referral",
                "value": "return to clinic after completion of investigations to review results and discuss ongoing management strategy"
            }
        ]
    }
}